Ticker

Imunon (NASDAQ: IMNN - Get Free Report) will likely be posting its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Imunon to post earnings of ($1.54) per share for the quarter. Investors can check the company's upcoming Q4 2025 earning summary page for the latest details on the call scheduled for

Imunon (NASDAQ: IMNN - Get Free Report) and Pharma Mar (OTCMKTS:PHMMF - Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, earnings, institutional ownership, dividends, analyst recommendations, valuation and profitability. Valuation and Earnings This table compares Imunon and Pharma

Strategic Restructuring Eliminates Expenses Not Essential to the Phase 3 Study Khursheed Anwer, Ph.D., Executive Vice President and Chief Scientific Officer, will retire after nearly 12 years at the company Phase 3 Study enrollment remains ahead of schedule and advances the company toward future BLA filing LAWRENCEVILLE, N.J.

Imunon (NASDAQ: IMNN - Get Free Report) and Allogene Therapeutics (NASDAQ: ALLO - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, institutional ownership, profitability and analyst recommendations. Profitability This table compares Imunon and Allogene Therapeutics'

Shares of Imunon, Inc. (NASDAQ: IMNN - Get Free Report) have earned a consensus rating of "Hold" from the five analysts that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and two have assigned a buy recommendation to the